Epigentic regulation of 11β-hydroxysteroid dehydrogenase type 2 expression

Journal of Clinical Investigation

Volumn 114, Issue 8, 2004, Pages 1146-1157

  Alikhani Koopaei, Rasoul ^a   Fouladkou, Fatemeh ^a   Frey, Felix J ^a   Frey, Brigitte M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; HYDROXAMIC ACID; PROCAINAMIDE; TRANSCRIPTION FACTOR; TRICHOSTATIN A;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA BINDING; DNA METHYLATION; ENZYME ACTIVITY; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC CODE; GENETIC TRANSCRIPTION; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; ANIMAL; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; TUMOR CELL LINE; WISTAR RAT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ANIMALS; AZACITIDINE; BASE SEQUENCE; BLOOD PRESSURE; CELL LINE, TUMOR; CPG ISLANDS; DNA; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HUMANS; HYDROCORTISONE; HYDROXAMIC ACIDS; HYPERTENSION; MOLECULAR SEQUENCE DATA; PROCAINAMIDE; PROMOTER REGIONS (GENETICS); RATS; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 85047694610     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI21647     Document Type: Article

References (44)

1. Albiston, A.L., Obeyesekere, V.R., Smith, R.E., and Krozowski, Z.S. 1994. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 105:R11-R17.
2. Tannin, G.M., Agarwal, A.K., Monder, C., New, M.I., and White, P.C. 1991. The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J. Biol. Chem. 266:16653-16658.
3. Escher, G., Galli, I., Vishwanath, B.S., Frey, B.M., and Frey, F.J. 1997. Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle. J. Exp. Med. 186:189-198.
4. Frey, F.J., Odermatt, A., and Frey, B.M. 2004. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr. Opin. Nephrol. Hypertens. 13:451-458.
5. Odermatt, A., Arnold, P., Stauffer, A., Frey, B.M., and Frey, F.J. 1999. The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J. Biol. Chem. 274:28762-28770.
6. Kotelevtsev, Y., et al. 1999. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 103:683-689.
7. Stewart, P.M., Corrie, J.E., Shackleton, C.H., and Edwards, C.R. 1988. Syndrome of apparent mineralocorticoid excess. A defect in the cortisolcortisone shuttle. J. Clin. Invest. 82:340-349.
8. Lovati, E., et al. 1999. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. J. Clin. Endocrinol. Metab. 84:3745-3749.
9. Agarwal, A.K., et al. 2000. CA-Repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension. 36:187-194.
10. Watson, B., Jr., et al. 1996. Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension. 28:478-482.
11. Zaehner, T., Plueshke, V., Frey, B.M., Frey, F.J., and Ferrari, P. 2000. Structural analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene in endstage renal disease. Kidney Int. 58:1413-1419.
12. Agarwal, A.K., and White, P.C. 1996. Analysis of the promoter of the NAD+ dependent 11beta-hydroxysteroid dehydrogenase (HSD11K) gene in JEG-3 human choriocarcinoma cells. Mol. Cell. Endocrinol. 121:93-99.
13. Nawrocki, A.R., Goldring, C.E., Kostadinova, R.M., Frey, F.J., and Frey, B.M. 2002. In vivo foot-printing of the human 11beta-hydroxysteroid dehydrogenase type 2 promoter: evidence for cell-specific regulation by Sp1 and Sp3. J. Biol. Chem. 277:14647-14656.
14. Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G., and Baylin, S.B. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:103-107.
15. Lin, X., et al. 2001. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 61:8611-8616.
16. Rebuffat, A.G., et al. 2004. The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist. Mol. Cell. Endocrinol. 214:27-37.
17. Jones, P.A. 1999. The DNA methylation paradox. Trends Genet. 15:34-37.
18. Jaenisch, R., and Bird, A. 2003. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33(Suppl.):245-254.
19. Grunau, C., Clark, S.J., and Rosenthal, A. 2001. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 29:E65.
20. Agarwal, A.K., Rogerson, F.M., Mune, T., and White, P.C. 1995. Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase. Genomics. 29:195-199.
21. Gronostajski, R.M. 2000. Roles of the NF1/CTF gene family in transcription and development. Gene. 249:31-45.
22. Ballestar, E., and Wolffe, A.P. 2001. Methylated-CpG-binding proteins. Targeting specific gene repression. Eur. J. Biochem. 268:1-6.
23. Meehan, R.R., Lewis, J.D., McKay, S., Kleiner, E.L., and Bird, A.P. 1989. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell. 58:499-507.
24. Ng, H.H., et al. 1999. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23:58-61.
25. Mulholland, N.M., Soeth, E., and Smith, C.L. 2003. Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation. Oncogene. 22:4807-4818.
26. Sowa, Y., et al. 1999. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacecylase inhibitor. Cancer Res. 59:4266-4270.
27. Tate, P.H., and Bird, A.P. 1993. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 3:226-231.
28. Constancia, M., Pickard, B., Kelsey, G., and Reik, W. 1998. Imprinting mechanisms. Genome Res. 8:881-900.
29. Zhu, W.G., et al. 2003. Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol. Cell. Biol. 23:4056-4065.
30. Yin, H., and Blanchard, K.L. 2000. DNA methylation represses the expression of the human erythropoietin gene by two different mechanisms. Blood. 95:111-119.
31. Ben-Hattar, J., Beard, P., and Jiricny, J. 1989. Cytosine methylation in CTF and Sp1 recognition sites of an HSV tk promoter: effects on transcription in vivo and on factor binding in vitro. Nucleic Acids Res. 17:10179-10190.
32. Osada, S., Daimon, S., Nishihara, T., and Imagawa, M. 1996. Identification of DNA binding-site preferences for nuclear factor 1-A. FEBS Lett. 390:44-46.
33. Gronostajski, R.M. 1987. Site-specific DNA binding of nuclear factor I: effect of the spacer region. Nucleic Acids Res. 15:5545-5559.
34. Reese, B.E., Bachman, K.E., Baylin, S.B., and Rountree, M.R. 2003. The methylated-CpG binding protein MBD1 interacts with the p150 subunit of chromatin assembly factor 1. Mol. Cell. Biol. 23:3226-3236.
35. Hebbar, P.B., and Archer, T.K. 2003. Nuclear factor 1 is required for both hormone-dependent chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter. Mol. Cell. Biol. 23:887-898.
36. Feng, Q., and Zhang, Y. 2001. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15:827-832.
37. Rabbitt, E.H., et al. 2002. Prereceptor regulation of glucocorticoid action by 11beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. FASEB J. 16:36-44.
38. Ferrari, P., Sansonnens, A., Dick, B., and Frey, F.J. 2001. In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice. Hypertension. 38:1330-1336.
39. Lanz, C.B., et al. 2001. Fluid shear stress reduces 11ss-hydroxysteroid dehydrogenase type 2. Hypertension. 37:160-169.
40. Baer, P.C., Nockher, W.A., Haase, W., and Scherberich, J.E. 1997. Isolation of proximal and distal tubule cells from human kidney by immunomagnetic separation. Technical note. Kidney Int. 52:1321-1331.
41. Singal, R., Ferris, R., Little, J.A., Wang, S.Z., and Ginder, G.D. 1997. Methylation of the minimal promoter of an embryonic globin gene silences transcription in primary erythroid cells. Proc. Natl. Acad. Sci. U. S. A. 94:13724-13729.
42. Song, S.H., et al. 2001. Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5′ CpG island in human gastric carcinoma cells. Cancer Res. 61:4628-4635.
43. Schumacher, M., et al. 2002. Salt-sensitivity of blood pressure and decreased 11beta-hydroxysteroid dehydrogenase type 2 activity after renal transplantation. Transplantation. 74:66-72.
44. Shackleton, C.H. 1993. Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J. Steroid Biochem. Mol. Biol. 45:127-140.